9 -

9 - Satoh T, Xu R-H, Cheol Chung H et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. Journal of Clinical Oncology. 2014;32(19):2039-49 [link]